DK1146896T3 - Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger - Google Patents

Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger

Info

Publication number
DK1146896T3
DK1146896T3 DK00904496T DK00904496T DK1146896T3 DK 1146896 T3 DK1146896 T3 DK 1146896T3 DK 00904496 T DK00904496 T DK 00904496T DK 00904496 T DK00904496 T DK 00904496T DK 1146896 T3 DK1146896 T3 DK 1146896T3
Authority
DK
Denmark
Prior art keywords
human insulin
modified
acylated
formulations
formulations containing
Prior art date
Application number
DK00904496T
Other languages
Danish (da)
English (en)
Inventor
Kingman Ng
Shun Li
Eric Alan Watts
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1146896T3 publication Critical patent/DK1146896T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK00904496T 1999-01-26 2000-01-26 Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger DK1146896T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11729199P 1999-01-26 1999-01-26
PCT/US2000/001627 WO2000043034A2 (en) 1999-01-26 2000-01-26 Monodisperse hexameric acylated insulin analog formulations

Publications (1)

Publication Number Publication Date
DK1146896T3 true DK1146896T3 (da) 2002-09-02

Family

ID=22372048

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00904496T DK1146896T3 (da) 1999-01-26 2000-01-26 Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger

Country Status (9)

Country Link
EP (1) EP1146896B1 (ja)
JP (1) JP2002535287A (ja)
AT (1) ATE220917T1 (ja)
AU (1) AU2624400A (ja)
DE (1) DE60000288T2 (ja)
DK (1) DK1146896T3 (ja)
ES (1) ES2180511T3 (ja)
PT (1) PT1146896E (ja)
WO (1) WO2000043034A2 (ja)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
EP1506003A1 (en) * 2002-05-07 2005-02-16 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
ATE496064T1 (de) * 2002-05-07 2011-02-15 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
CA2504287A1 (en) 2002-11-26 2004-06-10 Nobex Corporation Natriuretic compounds, conjugates, and uses thereof
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
KR101276754B1 (ko) * 2004-07-19 2013-06-19 바이오콘 리미티드 인슐린―올리고머 접합체，제형 및 이들의 용도
ATE519780T1 (de) * 2005-12-28 2011-08-15 Novo Nordisk As Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
PL2074141T3 (pl) 2006-09-22 2017-02-28 Novo Nordisk A/S Analogi insuliny oporne na proteazę
CN101674812B (zh) 2007-04-30 2013-12-11 诺沃-诺迪斯克有限公司 干燥蛋白组合物的方法、干燥的蛋白组合物和包含干燥的蛋白的药物组合物
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
EP2254905B1 (en) 2008-03-14 2016-12-14 Novo Nordisk A/S Protease-stabilized insulin analogues
EP2910570B1 (en) 2008-03-18 2016-10-12 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
KR20110085985A (ko) 2008-10-30 2011-07-27 노보 노르디스크 에이/에스 하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
KR20150002777A (ko) 2012-04-11 2015-01-07 노보 노르디스크 에이/에스 인슐린 제제
CN104902922B (zh) 2012-11-13 2017-12-12 阿道恰公司 包含经取代阴离子化合物的速效胰岛素制剂
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
AU2014333979B2 (en) 2013-10-07 2018-02-15 Novo Nordisk A/S Novel derivative of an insulin analogue
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
SI3554534T1 (sl) * 2016-12-16 2021-09-30 Novo Nordisk A/S Farmacevtski sestavki, ki vsebujejo inzulin
JOP20190277B1 (ar) 2017-06-01 2023-09-17 Lilly Co Eli تركيبات إنسولين سريعة المفعول
AU2018317810A1 (en) 2017-08-17 2020-03-19 Novo Nordisk A/S Novel acylated insulin analogues and uses thereof
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
EP4013778A4 (en) * 2019-08-16 2023-09-13 Lamark Biotech PVT Limited FORMULATION OF INSULIN BASED ON CRYSTAL VACCINATION OF HYDROGELS AND METHOD THEREOF

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2167751T5 (es) * 1996-06-20 2012-03-30 Novo Nordisk A/S Preparaciones de insulina conteniendo un halogenuro
ES2242270T3 (es) * 1997-02-07 2005-11-01 Novo Nordisk A/S Cristalizacion de proteinas.
DE69924232D1 (de) * 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen

Also Published As

Publication number Publication date
ES2180511T3 (es) 2003-02-16
DE60000288D1 (de) 2002-08-29
WO2000043034A2 (en) 2000-07-27
PT1146896E (pt) 2002-10-31
AU2624400A (en) 2000-08-07
EP1146896B1 (en) 2002-07-24
EP1146896A2 (en) 2001-10-24
WO2000043034A3 (en) 2000-12-28
ATE220917T1 (de) 2002-08-15
JP2002535287A (ja) 2002-10-22
DE60000288T2 (de) 2003-01-16

Similar Documents

Publication Publication Date Title
DK1146896T3 (da) Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger
WO2002043750A8 (en) Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
HUP0100243A2 (hu) Inzulint és/vagy inzulin-analógokat és azok származékait tartalmazó oldhatatlan készítmények, eljárás azok előállítására és alkalmazásuk a vércukor szintjének szabályozására
EP1808438A3 (en) Purification and stabilization of peptide and proteins in pharmaceutical agents
EP1234586A3 (en) Hepatoselective pharmaceutical actives
WO2007130113A3 (en) Parathyroid hormone analogues and methods of use
DE58901401D1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
MY121291A (en) Fracture healing using pthrp analogs
WO2003053346A3 (en) Systems and methods for treating patients with processed lipoaspirate cells
EA200000748A1 (ru) Способ введения мономерных аналогов инсулина
AU563642B2 (en) Oral antidiabetic composition
NO20005625L (no) Anvendelse av toremifen og dens metabolske analoger, og deres farmasoytisk akseptable salter, estere, N-oksider og blanding av disse, i fremstilling av et farmasoytisk preparat for behandling av prostataintraepitelisk neoplasi (PIN)
HK1037142A1 (en) Phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate for the treatment of neoplastic diseases
WO1996024370B1 (en) Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
BR9811755A (pt) Peptìdeo, processo para o tratamento da obesidade em um animal, uso de um peptìdeo, e, composição farmacêutica
KR950700326A (ko) 파라토르몬 단편, 이것의 제조방법 및 이것을 함유하는 약제(parathyroid hormone fragments, their preparation and medicaments containing the same)
CA2522146A1 (en) Uptake of macromolecules
AR036591A1 (es) Uso de la hl en hiperestimulacion ovarica controlada
BR9006746A (pt) Peptideo fisiologicamente ativo e agente regulador do metabolismo de calcio
PT97878A (pt) Processo para a preparacao de uma composicao farmaceutica para uso oftalmico contendo hexetidina ou seus derivados ou sais
MX9704388A (es) Incremento de la concentracion de creatina y glicogeno en musculos.
TH12479B (th) สูตรผสมของสารคล้ายอินซูลิน